Loading...
Market
What will be Zevra Therapeutics' revenue growth rate in 2024?
3
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Annual financial reports from Zevra Therapeutics
Story
Zevra's Miplyffa Receives FDA Approval, Eligible for $150M Voucher
Sep 20, 2024, 03:00 PM
Zevra Therapeutics, formerly KemPharm, has received FDA approval for its drug Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. This approval makes Miplyffa the first treatment to be approved for NPC. The approval also makes Zevra eligible to receive a Priority Review Voucher worth approximately $150 million. Miplyffa is approved for use in combination with miglustat for patients aged 2 and older. The PDUFA date for the drug was September 21, 2024.
View original story
Similar markets
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%